ACCC says agreement to settle Revlimid patent suit could violate cartel laws

Intellectual Property 2022-03-23 2:53 pm By Cat Fredenburgh | Melbourne

The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.